-
Nature Genetics: Mapping unique and detailed molecular maps of endometriosis
Time of Update: 2023-02-02
”essaySingle-cell transcriptomic analysis of endometriosis Researchers have created a unique and detailed molecular map of endometriosis to help improve treatment options for millions of women with the disease.
-
【Nature】The weakness of the new crown virus has been found! Boston University and Harvard Medical School open new ways to eliminate COVID
Time of Update: 2023-02-01
Referrals, live broadcasts/events01/12 14:00-16:00 OnlineOlink Multiomics Cohort ForumScan the code to participate for free03/02-03 09:00-18:00 ShanghaiThe 2nd Yangtze River Delta Single-cell Omics Technology Application ForumScan the code to participate for freeThis article is the original of Translational Medicine Network, please indicate the source for reprintingWritten by JevinThe new coronavirus usually infects humans through the respiratory tract and causes damage to the respiratory system and various organs of the human body.
-
Blood: Ph+ALL patients do not benefit from allogeneic hematopoietic cell transplantation
Time of Update: 2023-01-04
Overall, the results of this retrospective study suggest that adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who achieve a complete molecular response within 90 days of initiating treatment do not derive a survival benefit from allo-HCT at first complete response.
-
When benefit-risk assessment becomes the focus, a new round of supply-side reform of innovative drugs begins
Time of Update: 2022-11-26
According to the Draft Opinion, the marketing application of innovative drugs: the benefits of drugs – risk assessment is a key process in regulatory decision-making, which ultimately determines whether it is approved.
-
Pleural effusions recur! Anti-tuberculosis treatment failed, I didn't expect it to be this disease
Time of Update: 2022-11-15
During hospitalization, he underwent multiple right-sided thoracentesis aspiration under color Doppler ultrasound positioning, and chest CT after half a month of treatment showed a decrease in pleural effusion, and he is currently treated with oral isoniazid, rifampicin, ethylaminobutol hydrochloride, pyrazinamide anti-tuberculosis therapy, and liver protection and support therapy for more than 3 months.
-
Nat Rev Cancer: The future direction of NK cell therapy
Time of Update: 2022-10-19
In any case, CAR-NK cell therapy is a promising clinical research field with good safety and preliminary efficacy for some cancer patients.
In any case, CAR-NK cell therapy is a promising clinical research field with good safety and preliminary efficacy for some cancer patients.
-
CSH Innovation Forum| Han Yue, Xu Yajing, Wang Yu, Zhao Mingfeng, Yi Hongmei invite you to join the academic feast on September 23-25 - the 17th National Hematology Academic Conference of the Chinese
Time of Update: 2022-10-14
Listening to the sound of blood and perceiving the rhythm of life, the much-anticipated "17th National Hematology Academic Conference of the Chinese Medical Association" will be grandly opened on Sep
-
Chinese Medicine Innovation Dragon Hair Wei! 3 exclusive proprietary Chinese medicines sold for 10 billion
Time of Update: 2022-09-20
2019H1-2022H1 R&D investment of Yiling Pharmaceutical (: 100 million yuan) Source: Company Announcement Since 2020, 16 new Chinese medicine drugs (in terms of drug name + enterprise, excluding APIs) have been approved for listing, covering anti-tumor, respiratory system, nervous system, gynecology, orthopedics and other therapeutic fields.
-
The first HER2+ NSCLC drug was born
Time of Update: 2022-08-20
On August 11, the FDA granted accelerated approval for a new indication of Daiichi Sankyo’s Enhertu (fam-trastuzumab deruxtecan-nxki, DS-8201) for unresectable or metastatic HER2 mutation-positive adult non-small cell lung cancer who have previously received systemic therapy (NSCLC) patients .
-
New hair loss drug is expected to be launched to restore 80% of hair growth
Time of Update: 2022-08-12
Retrieved May 20, 2022, from https:// /news-releases/chmp-recommends-approval-of-lilly-and-incytes-olumiant-baricitinib-as-the-first-and-only-centrally-authorized-treatment-for-adults-with-severe-alopecia-areata -aa-301551999.
Retrieved May 20, 2022, from https:// /news-releases/chmp-recommends-approval-of-lilly-and-incytes-olumiant-baricitinib-as-the-first-and-only-centrally-authorized-treatment-for-adults-with-severe-alopecia-areata -aa-301551999.
Retrieved May 20, 2022, from https:// /news-releases/chmp-recommends-approval-of-lilly-and-incytes-olumiant-baricitinib-as-the-first-and-only-centrally-authorized-treatment-for-adults-with-severe-alopecia-areata -aa-301551999.
Retrieved May 20, 2022, from https:// /news-releases/chmp-recommends-approval-of-lilly-and-incytes-olumiant-baricitinib-as-the-first-and-only-centrally-authorized-treatment-for-adults-with-severe-alopecia-areata -aa-301551999.
Retrieved May 20, 2022, from https:// /news-releases/chmp-recommends-approval-of-lilly-and-incytes-olumiant-baricitinib-as-the-first-and-only-centrally-authorized-treatment-for-adults-with-severe-alopecia-areata -aa-301551999.
-
Long-lasting wrinkle removal
Time of Update: 2022-06-09
Retrieved Dec 5, 2018, from https:// [3] Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery .
-
Fosun Pharma, Huahai Pharma Receive MMP License to Produce Generic Drugs of Novel Coronavirus Oral Drug Nematevir
Time of Update: 2022-04-26
On March 18, Fosun Pharma and Huahai Pharmaceutical announced separately that the MPP (Medicine Patent Pool Organization) granted them the use of related patents and know-how to produce generic drugs
-
Lancet Oncol: Addition of Isatuximab to the pomalidomide-dexamethasone regimen significantly prolongs overall survival in patients with relapsed/refractory multiple myeloma
Time of Update: 2022-03-05
The primary analysis of the ICARIA-MM study showed that the addition of the CD38 antibody Isatuximab to the pomalidomide-dexamethasone regimen significantly improved progression-free survival in patients with relapsed and refractory multiple myeloma .
-
Scientists map skin cells that cause diabetic foot ulcers
Time of Update: 2022-01-25
Scientists have mapped the cellular landscape in the treatment of diabetic foot ulcers and non-healers using a cutting-edge technique called single-cell RNA-sequencing analysis, which provides deep insight into cellular function and disease development, revealing that gene expression in individual cells in tissues is determined by various types of cells .
-
Antibiotic treatment of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, a list of recommendations from European guidelines
Time of Update: 2022-01-09
CRPA antibiotic selection ➤ For patients with severe infection caused by refractory and drug-resistant CRPA (DTR-CRPA), it is recommended to use ceftaroza/tazobactam ( If effective in vitro) (conditional recommendation, very low quality of evidence) .
